312 related articles for article (PubMed ID: 16979445)
1. Systemic targeted radionuclide therapy: potential new areas.
Wong JY
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S74-82. PubMed ID: 16979445
[TBL] [Abstract][Full Text] [Related]
2. Basic immunology of antibody targeted radiotherapy.
Wong JY
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S8-14. PubMed ID: 16979446
[TBL] [Abstract][Full Text] [Related]
3. The promise of targeted {alpha}-particle therapy.
Mulford DA; Scheinberg DA; Jurcic JG
J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
[TBL] [Abstract][Full Text] [Related]
4. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
5. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.
Steiner M; Neri D
Clin Cancer Res; 2011 Oct; 17(20):6406-16. PubMed ID: 22003068
[TBL] [Abstract][Full Text] [Related]
6. Antibody-based targeted radiation to pediatric tumors.
Modak S; Cheung NK
J Nucl Med; 2005 Jan; 46 Suppl 1():157S-63S. PubMed ID: 15653664
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Reilly RM
J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
[No Abstract] [Full Text] [Related]
8. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
9. Technological advances in radioimmunotherapy.
Dearling JL; Pedley RB
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):457-69. PubMed ID: 17537620
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey RM; Goldenberg DM
J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
[TBL] [Abstract][Full Text] [Related]
11. Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology.
Bentzen SM
Cancer Treat Res; 2008; 139():41-62. PubMed ID: 18236711
[No Abstract] [Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Isobologram analysis of triple therapies.
Niyazi M; Belka C
Radiat Oncol; 2006 Oct; 1():39. PubMed ID: 17044920
[TBL] [Abstract][Full Text] [Related]
14. Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).
Wessels BW; Syh JH; Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S39-45. PubMed ID: 16979438
[TBL] [Abstract][Full Text] [Related]
15. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
16. Current status of therapy of solid tumors.
Jhanwar YS; Divgi C
J Nucl Med; 2005 Jan; 46 Suppl 1():141S-50S. PubMed ID: 15653662
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of prostate cancer.
Smith-Jones PM
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):297-304. PubMed ID: 15640793
[TBL] [Abstract][Full Text] [Related]
18. Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness.
Vassiliou V; Bruland O; Janjan N; Lutz S; Kardamakis D; Hoskin P
Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):665-7. PubMed ID: 19700270
[No Abstract] [Full Text] [Related]
19. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
20. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
Rao DV; Howell RW
J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
